KPV
KPV (Lys-Pro-Val) — Alpha-MSH Tripeptide
KPV is the C-terminal tripeptide fragment of alpha-Melanocyte-Stimulating Hormone (α-MSH). It retains the anti-inflammatory potency of the parent molecule without its melanogenic and hormonal side effects. Research focuses primarily on inflammatory bowel disease, wound healing, and anti-inflammatory applications across multiple organ systems.
Mechanism of Action
KPV binds melanocortin receptors (MC1R and MC3R) expressed on immune cells, epithelial cells, and neurons. Receptor activation suppresses NF-κB-mediated pro-inflammatory cytokine production (TNF-α, IL-6, IL-8) and drives anti-inflammatory pathways including IL-10 upregulation.
In the gut, KPV is particularly effective because it is taken up intact by intestinal epithelial cells via the PepT1 transporter — enabling oral bioavailability for gastrointestinal applications. This makes it one of the few peptides where oral dosing is pharmacologically validated for local GI effects.
KPV also activates melanocortin pathways in the CNS, contributing to fever reduction and systemic anti-inflammatory signalling. Its small size (3 amino acids) enables good tissue penetration including topical applications.
Research Evidence
KPV has robust preclinical data for inflammatory bowel conditions (Crohn's disease, ulcerative colitis models) and wound healing. Oral nanoparticle formulations have been developed to improve colonic delivery.
Oral KPV Reduces Colitis in Murine Models via PepT1 Transport
Oral KPV loaded into nanoparticles and administered to DSS-induced colitis mice reduced colonic inflammation, mucosal damage scores, and pro-inflammatory cytokine levels significantly versus controls, establishing oral delivery feasibility.
Typical Research Protocol
For systemic anti-inflammatory effects, SC dosing is preferred. For GI applications (IBD, leaky gut), oral KPV formulated in capsules or blended with BPC-157 is the most relevant delivery approach.
Safety Profile
Reported Side Effects
- Injection site redness (SC)
- Mild skin darkening (possible — MC1R activity)
- Headache (rare)
Contraindications
- Known melanocortin sensitivity
- Pregnancy (insufficient data)
- Active melanoma (MC1R concern)
Common Research Stacks
Frequently Asked Questions
Does KPV cause skin darkening?
KPV binds MC1R — the same receptor responsible for skin pigmentation. However, KPV's melanogenic activity is far lower than full α-MSH. At research doses, significant skin darkening has not been consistently reported. Those with fair skin or concerns about pigmentation should monitor closely.
How does KPV compare to BPC-157 for gut healing?
KPV and BPC-157 address gut healing through different mechanisms. KPV suppresses immune-mediated inflammation (NF-κB, TNF-α, IL-6) via melanocortin receptors — making it particularly relevant for inflammatory bowel disease (IBD) where immune overactivation is the driver. BPC-157 drives mucosal regeneration and vascularisation through the NO/VEGF pathway. For IBD, KPV is potentially more targeted; for ulcer or injury repair, BPC-157 has stronger evidence.
Can KPV be taken orally?
Yes — KPV is one of the few peptides where oral administration is pharmacologically validated for local GI effects. It is transported intact across intestinal epithelium by the PepT1 dipeptide transporter. Oral capsule or liquid formulations are specifically studied for colitis and IBD indications. For systemic anti-inflammatory effects beyond the gut, SC injection is preferred.
What conditions is KPV being studied for?
Primary research applications include: inflammatory bowel disease (Crohn's disease, ulcerative colitis), wound healing (particularly chronic or inflamed wounds), skin conditions (psoriasis, contact dermatitis), and general systemic anti-inflammatory support. Its melanocortin receptor mechanism is also studied for fever modulation and sepsis research.
Is there a difference between KPV and α-MSH?
α-MSH is the full 13-amino-acid parent peptide. KPV is its C-terminal tripeptide (amino acids 11-13). KPV retains the anti-inflammatory potency of α-MSH via melanocortin receptors but lacks the N-terminal sequence responsible for melanogenesis (skin darkening) and most hormonal effects. This makes KPV safer for chronic use where skin pigmentation is a concern.
Key Research References
- Kannengiesser K et al. (2008). Melanocyte-stimulating hormone peptide inhibits NF-κB activation in gut. Gastroenterology.
- Brzoska T et al. (2008). Alpha-MSH and related tripeptides: biochemistry, anti-inflammatory and protective effects. J Leukoc Biol.
Explore more Recovery research compounds
Browse Recovery →